Login to Your Account

Genmab Gets Accelerated OK for Arzerra in Refractory CLL

By Cormac Sheridan

Wednesday, October 28, 2009
Genmab A/S passed its most significant milestone to date by obtaining its first drug approval, for ofatumumab (Arzerra) as a therapy for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab (Campath). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription